CONTROL study results show improved tolerability of NERLYNX® (neratinib) with all the investigated diarrhoea prophylaxis strategies
Puma regains China rights to Nerlynx and amends deal with Fabre
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Puma Biotech Expands Pierre Fabre License to Add Countries
Pierre Fabre étend sa collaboration avec Puma Biotechnology
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in
Puma Bio: Sifting Through The Q4 Earnings Report (NASDAQ:PBYI) | Seeking Alpha
CONTROL study results show improved tolerability of NERLYNX® (neratinib) with all the investigated diarrhoea prophylaxis strategies | Pierre Fabre Pharma Norden AB
Pierre Fabre engagements | NERLYNX
Puma regains China rights to Nerlynx and amends deal with Fabre
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Pierre Fabre and ValenzaBio collaborate on anti-IGF-1R antibody for TE
Fight against cancer : our therapeutic responses | Pierre Fabre
Puma regains China rights to Nerlynx and amends deal with Fabre
Puma and CANBridge cancel licensing deal for $20m
Puma Biotechnology | Evaluate
Will Puma Biotechnology Break Out of Its Rut in 2020? | The Motley Fool
Pierre Fabre étend ses droits sur le Nerlynx de Puma Biotechnology
Partners of the Pierre Fabre Group: from health to beauty
Puma Biotechnology: Finding Bullish Indications At The End Of 2019 (NASDAQ:PBYI) | Seeking Alpha
Fight against cancer : our therapeutic responses | Pierre Fabre
Pierre Fabre pens oncology pact with atomic energy spinout | Fierce Biotech
Pierre Fabre amends license agreement with Puma Biotechnology - European Biotechnology
